![]() |
市場調查報告書
商品編碼
1504160
單株抗體的市場規模,佔有率,預測,趨勢分析:產品類型,用途,供給來源,生產,各終端用戶 - 2031年前的世界預測Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type Application, Source, Production, End User - Global Forecast to 2031 |
預計到 2031 年,全球單株抗體市場將達到 4,498 億美元,2024 年至 2031 年複合年增長率為 11.2%。
單株抗體市場規模、佔有率、預測、趨勢分析:產品類型(治療、研究、診斷)應用(腫瘤學、免疫學、心臟病學、神經學)、來源(人源化、小鼠、人類),依生產和最終用戶劃分 -到 2031 年的全球預測
該報告經過廣泛的二級和一級研究以及對單株抗體市場情景的深入分析,對主要行業驅動因素、限制因素、課題和機會進行了分析。單株抗體市場的成長是由全球癌症和自體免疫疾病的高負擔、臨床試驗和研究資金的增加、生物製藥行業的增長、傳染患者病率的上升以及對蛋白質組學和基因組學的需求不斷增加所推動的。然而,替代診斷測試的可用性以及抗體開發的高成本和時間限制了市場的成長。
此外,製藥和生物技術公司的研發投入增加,抗體在臨床試驗和醫學研究中的應用擴大,新興國家的研究活動增加,識別新生物標誌物的需求日益增長,以及旨在加強市場的診斷測試數量的增加預計將為市場成長創造機會。然而,抗體測試的準確性低、製造成本高、對研究抗體的品質和穩定性的擔憂以及製造過程的複雜性是阻礙市場成長的課題。
(註:包含前5名公司的SWOT分析)
Monoclonal Antibodies Market Size, Share, Forecast, & Trends Analysis by Type (Therapeutic, Research, Diagnostic) Application (Oncology, Immunology, Cardiology, Neurology), Source (Humanized, Murine, Human), Production, End User-Global Forecast to 2031
The global monoclonal antibodies market is projected to reach $449.8 billion by 2031 at a CAGR of 11.2% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the monoclonal antibodies market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the monoclonal antibodies market is driven by the high burden of cancer and autoimmune diseases globally, increasing funding for clinical trials and research, growth in the biopharmaceutical industry, rising prevalence of infectious diseases, and increasing research in proteomics and genomics. However, the availability of alternative diagnostic tests and the high costs & time required for antibody development restrain the market's growth.
Furthermore, increasing R&D investments by pharmaceutical & biotech companies, expanding applications of antibodies in clinical trials and medical research, increasing research activities in developing countries, the rising need for new biomarker identification, and initiatives aimed at enhancing diagnostic testing are expected to create market growth opportunities. However, the inaccuracy of antibody tests, high manufacturing costs, concerns regarding the quality & stability of research antibodies, and complexities in the production process are some of the challenges impeding the market's growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2024). The key players operating in the monoclonal antibodies market are Novartis AG (Switzerland), Pfizer Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Amgen Inc. (U.S.), Bristol-Myers Squibb (U.S.), GSK plc (U.K.), Merck KGaA (Germany), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Johnson & Johnson (U.S.), Takeda Pharmaceutical Company Limited (Japan), Daiichi Sankyo Company (Japan), Biogen (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
Among the types covered in this report, in 2024, the therapeutic monoclonal antibodies segment is expected to account for the largest share of over 90.2% of the monoclonal antibodies market. The therapeutic monoclonal antibodies segment is further sub-segmented into oncology, autoimmune diseases, neurological diseases, infectious diseases, and other therapeutic areas. The large market share of this segment is attributed to the increasing approvals for the therapeutical monoclonal antibodies, rising demand for biosimilars, increasing prevalence of target disease, technological advancements in the formulation of antibodies, an increasing number of pipeline products, and fewer side effects of monoclonal antibodies. Additionally, with the increasing prevalence of cancer, the demand for monoclonal antibodies is also increasing for personalized cancer therapies. According to GLOBOCAN, the prevalence of cancer is expected to increase by 63.4% in 2045 from 2022.
Among the production processes covered in this report, in 2024, the in vitro process segment is expected to account for the largest share of the monoclonal antibodies market. The in vitro segment is further segmented into upstream process and downstream process. The in vitro process scales up antibody production without reliance on animal models and animal testing. It increases the production of MABs and also mitigates the ethical concerns associated with the use of animals, thus preferred over the in vivo process.
Among the sources covered in this report, in 2024, the human segment is expected to account for the largest share of the monoclonal antibodies market. Human sources are preferred for the production of monoclonal antibodies to increase treatment efficiency by reducing the risk of immunogenicity or adverse immune response. Key players are also using human sources for the development of monoclonal antibodies to improve the safety profile of MABs, production of stable human hybridomas, and ease of scaling up production.
Among the end users covered in this report, the hospitals segment is expected to account for the largest share of the monoclonal antibodies market. The large market share of this segment is attributed to the availability of MAB therapies in hospitals, the increasing number of hospitals in emerging economies, and the launch of dedicated monoclonal antibody facilities by hospitals.
An in-depth analysis of the geographical scenario of the global monoclonal antibodies market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.
In 2024, North America is expected to account for the largest share of over 34.9% of the monoclonal antibodies market. The largest share of the regional market is attributed to the presence of key players, availability of advanced antibody engineering technology, rising number of approvals, and supportive government initiatives for the development and use of monoclonal antibodies. For instance, in September 2023, the U.S. Department of Health and Human Services announced an initiative to give underinsured and uninsured Americans access to the COVID-19 monoclonal antibody treatment bebtelovimab even after the product availability in the commercial market.
Monoclonal Antibodies Market Assessment-by Type
Note: 1) Other Research Areas include Ophthalmology and Rare Diseases
2) Other Research Technologies include electrophoretic mobility shift assay (EMSA) and enzyme-linked immunospot (ELISPOT) assay
3) Other Diagnostic Applications include Alzheimer's, autoimmune diseases, cardiac diseases, and diabetes.
4) Other Diagnostic Technologies include Immunofluorescence, flow cytometry, in situ hybridization, dot blot, and radioimmunoassay.
5) Other Therapeutic Areas include cardiac diseases, diabetes, ophthalmology, and hematology
Monoclonal Antibodies Market Assessment-by Production Process
Monoclonal Antibodies Market Assessment-by Source
Note: Other Sources include goat, sheep, chicken, and llama
Monoclonal Antibodies Market Assessment-by End User
Note: Other End Users include academic & research institutes, nursing centers, and long-term care centers
Monoclonal Antibodies Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)